spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  LDL cholesterol 

 HSMN NewsFeed - 2 Jan 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Feb 2019
Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 27 Jun 2018
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2017
Regeneron and Sanofi Announce Kevzara(R) (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Apr 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Apr 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara(R) (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 9 Feb 2017
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Jan 2017
Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 4 Jan 2017
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2016
Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent(R) (dupilumab) Accepted for Review by the EMA
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2016
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 12 Sep 2016
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent(R) (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 14 Apr 2016
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Apr 2016
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 11 Mar 2016
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Oct 2015
Regeneron Announces EU Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce FDA Approval of Praluent(R) (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Oct 2014
Hanson Medical Systems Becomes Preferred Distributor for PTS Diagnostics' CardioChek Family of Products
Diagnostics Distribution
 HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals
 HSMN NewsFeed - 24 Jan 2013
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Aug 2009
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe)
Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 4 Aug 2009
FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 8 Jun 2009
Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2009
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2008
Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2008
Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Aug 2008
Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke in Patients with Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 3 Jun 2008
Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
Diagnostics Cardiology
 HSMN NewsFeed - 31 May 2008
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2008
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2008
Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Feb 2008
Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2008
Robert A. Scott, M.D., Appointed Chief Medical Officer of Cerenis Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 14 Jan 2008
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Dec 2007
FDA Advisory Panel Recommends Against Approval of Merck's NDA for Non-prescription MEVACOR(R) (lovastatin) 20 mg
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 Nov 2007
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Nov 2007
Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2007
Genzyme Launches Cholestagel(R) in Europe
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Oct 2007
FDA Approves Genzyme's Renvela(TM) for Dialysis Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Aug 2007
Merck Announces FDA Acceptance of NDA for CORDAPTIVE(TM) (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
FDA Grants CLIA Waived Status to Cholestech for New Combined Test Panel
Diagnostics FDA
 HSMN NewsFeed - 11 Jul 2007
ProEthic Pharmaceuticals Enters Into U.S. Licensing and Distribution Agreement for Lipofen
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 10 Jul 2007
Cipher Pharmaceuticals enters into U.S. licensing and distribution agreement for Lipofen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Jun 2007
New Study Demonstrates Colesevelam HCl Lowers Both A1C and LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 8 Jun 2007
Schering-Plough and Bayer Healthcare Announce Availability of ZETIA in Japan, the First Cholesterol-Lowering Agent With a Novel Mechanism of Action Approved in Japan in 18 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Apr 2007
Multi-Center Clinical Study on Variations in Blood Viscosity
Devices Cardiology
 HSMN NewsFeed - 20 Apr 2007
Abbott Submits New Drug Application for Combination Niaspan(R)/Simvastatin Tablet
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2007
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Jan 2007
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Dec 2006
Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2006
Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor (atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2006
Study Shows Inflammatory Enzyme Lp-PLA2 Predicts Recurrent Stroke
Diagnostics Cardiology Neurology
 HSMN NewsFeed - 22 Oct 2006
Study Results Found Low-Dose Orlistat (60 mg) Demonstrates Significant Reduction in LDL Cholesterol While Providing Weight Loss for Up to Two Years
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
FDA Approves New Label for VYTORIN(R) (ezetimibe/simvastatin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Devices
 HSMN NewsFeed - 1 Jun 2006
Isis Pharmaceuticals Receives Orphan Drug Status for ISIS 301012 for the Treatment of Homozygous Familial Hypercholesterolemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2006
Biovail to Promote Novartis' Lescol(R) Franchise in Canada; Lescol(R) Provides Treatment Option for Patients Who Need a Statin to Reduce Cardiovascular Risk
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 67

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 67 additional stories matching:
LDL cholesterol
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.